Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 20/20 | 0.89 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.89 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.89 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL736682 | 0.94 | HSD11B1 (1.00) | HSD11B1CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL958399 | 0.94 | HSD11B1 (1.00) | HSD11B1CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL3646090 | 0.94 | HSD11B1 (1.00) | HSD11B1CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL958400 | 0.94 | HSD11B1 (1.00) | HSD11B1CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL961177 | 0.93 | HSD11B1 (0.82) | HSD11B1CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL961176 | 0.93 | HSD11B1 (0.82) | HSD11B1CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL961174 | 0.93 | HSD11B1 (0.82) | HSD11B1CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL3640399 | 0.93 | HSD11B1 (0.82) | HSD11B1CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL956321 | 0.92 | HSD11B1 (0.79) | HSD11B1CYP2C9CYP3A4CYP2C19KCNH2 | |
| SCHEMBL956320 | 0.92 | HSD11B1 (0.79) | HSD11B1CYP2C9CYP3A4CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569292-B2 | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20110263584-A1 | Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 | Vitae Pharmaceuticals, Inc. Boehringer Ingelheim International GmbH | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263584-A1 | Cyclic Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885CYP2C9 482/4885CYP3A4 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.